<DOC>
	<DOCNO>NCT03093116</DOCNO>
	<brief_summary>Phase 1 ass safety tolerability TPX-0005 via standard dose escalation scheme , determine recommend phase 2 dose . Phase 2 assess safety efficacy TPX-0005 .</brief_summary>
	<brief_title>A Study TPX-0005 Patients With Advanced Solid Tumors Harboring ALK , ROS1 , NTRK1-3 Rearrangements</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Key 1 . Histologically cytologically confirm diagnosis locally advance metastatic solid tumor ( include nonHodgkin Lymphoma ) ( Stage IV , AJCC v.7 ) harbor ALK , ROS1 , NTRK1 , NTRK2 , NTRK3 gene rearrangement protocol specify test . 2 . ECOG PS 01 . 3 . Age ≥18 ( age ≥ 20 age require local regulation ) . 4 . At least 1 measurable target lesion accord RECIST version 1.1 . CNSonly measurable disease define RECIST version 1.1 allow . 5 . Prior cytotoxic chemotherapy allow . 6 . Prior immunotherapy allow . 7 . Resolution acute toxic effect ( exclude alopecia ) prior anticancer therapy National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Version 4.03 Grade less equal 1 . 8 . Patients asymptomatic CNS involvement allow . 9 . Life expectancy ≥ 3 month . Key 1 . Concurrent participation another therapeutic clinical trial . 2 . Symptomatic CNS involvement . 3 . Any following cardiovascular history past 6 month : myocardial infarction , unstable angina , coronary/ peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism , deep vein thrombosis , symptomatic bradycardia , requirement antiarrhythmic medication . 4 . History prolong QTc interval . 5 . Known active infection ( bacterial , fungal , viral include HIV positivity ) . 6 . Gastrointestinal disease ( e.g. , Crohn 's disease , ulcerative colitis , short gut syndrome ) malabsorption syndrome would impact drug absorption . 7 . Peripheral neuropathy ≥ Grade 2 . 8 . Known interstitial lung disease , interstitial fibrosis , history tyrosine kinase inhibitorinduced pneumonitis . Patients history prior radiation pneumonitis exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ALK Gene Rearrangement</keyword>
	<keyword>ROS1 Gene Rearrangement</keyword>
	<keyword>NTRK 1/2/3 Gene Rearrangement</keyword>
</DOC>